An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome : report of three cases
In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Immunotherapy - 13(2021), 4 vom: 01. März, Seite 289-295 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Filgueira, Lázaro Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/imt-2020-0235 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319610845 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319610845 | ||
| 003 | DE-627 | ||
| 005 | 20231225171821.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2020-0235 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319610845 | ||
| 035 | |a (NLM)33397150 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Filgueira, Lázaro Manuel |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome |b report of three cases |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CD6 molecule | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a IL-6 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus 2 | |
| 650 | 4 | |a cytokine-release syndrome | |
| 650 | 4 | |a itolizumab | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a CD6 antigen |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a itolizumab |2 NLM | |
| 650 | 7 | |a XQQ2RHV14N |2 NLM | |
| 700 | 1 | |a Cervantes, Julio Betancourt |e verfasserin |4 aut | |
| 700 | 1 | |a Lovelle, Orlando Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Herrera, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Figueredo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero, Jorge Alain |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Naivy |e verfasserin |4 aut | |
| 700 | 1 | |a Berrio, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Geidy |e verfasserin |4 aut | |
| 700 | 1 | |a Cepeda, Meylan |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, Mayra |e verfasserin |4 aut | |
| 700 | 1 | |a Saavedra, Danay |e verfasserin |4 aut | |
| 700 | 1 | |a Añe-Kouri, Ana Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Mazorra, Zaima |e verfasserin |4 aut | |
| 700 | 1 | |a Leon, Kalet |e verfasserin |4 aut | |
| 700 | 1 | |a Crombet, Tania |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero, Armando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d 2009 |g 13(2021), 4 vom: 01. März, Seite 289-295 |w (DE-627)NLM19257163X |x 1750-7448 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:4 |g day:01 |g month:03 |g pages:289-295 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/imt-2020-0235 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 4 |b 01 |c 03 |h 289-295 | ||